|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 5,721,244
What Does US Patent 5,721,244 Cover?
US Patent 5,721,244, titled "Method for the inhibition of HIV replication and growth," claims a specific method involving the use of antisense oligonucleotides targeting the HIV tat gene. The patent was granted on February 24, 1998, to facilitate innovation in antiviral therapies, specifically therapies that inhibit HIV by disrupting gene expression.
Scope of Patent Claims
Main Claims:
- A method of inhibiting HIV replication in a human cell comprising introducing an antisense oligonucleotide having a nucleotide sequence complementary to a selected sequence of the HIV tat gene, thereby preventing expression of the tat gene.
- The antisense oligonucleotide is between 8 to 30 nucleotides long.
- The sequence targeted is within the tat gene, specifically between nucleotides 540 to 720.
- The oligonucleotide is chemically modified to enhance stability, such as phosphorothioate backbones.
- The method applies to both in vitro and in vivo settings.
Dependent Claims:
- Variations in the oligonucleotide length.
- Specific chemical modifications to improve pharmacokinetics.
- Use of different delivery mechanisms, including liposomal systems.
- Targeting other regulatory regions within the HIV genome.
Claim Limitations
- Focused on antisense oligonucleotides complementary to the HIV tat gene.
- Restricted to sequences within a defined nucleotide range.
- Chemical modifications are limited to known stable structures.
- Application constrained to HIV, not broad-spectrum retroviruses.
Patent Landscape for HIV-Targeted Gene Inhibition
Timeline and Patent Filings:
- Filed: August 7, 1995
- Granted: February 24, 1998
- Expiration: August 7, 2015 (non-patent term adjustments possible)
- Extension: No known extensions applied
Related Patents:
- US Patent 5,928,950: Covers antisense approaches to other HIV genes (e.g., gag, pol).
- US Patent 5,951,973: Addresses delivery systems for antisense oligonucleotides.
- EP Patent 666,424: European counterpart describing similar antisense therapies against HIV.
Patent Families and International Applications
- Filed through the Patent Cooperation Treaty (PCT) (WO 1996/017521).
- Family includes filings in Europe, Japan, and Canada, broadening geographic protection.
- Patent family emphasizes antisense therapy for HIV and related retroviruses.
Competitive Landscape:
- Multiple pharmaceutical companies and biotech firms developed antisense technologies targeting HIV, including Isis Pharmaceuticals (now Ionis), Genta, and GlaxoSmithKline.
- Patents on delivery mechanisms, chemical modifications, and target sequences form a dense landscape.
- Some patents, especially those filed before 2000, have expired, allowing generics or biosimilar development.
Key Patent-Related Developments Since 1998
- Antisense Drugs Approvals: Mipomersen (Kynamro) and inotersen (Tegsedi) demonstrate antisense oligonucleotide success but target different diseases.
- HIV-specific Compounds: Several antisense HIV therapies entered clinical trials but faced challenges in efficacy and delivery.
- CRISPR and RNAi: Emerging gene-editing technologies challenged the scope of antisense patents, though not directly infringing.
Patent Validity and Freedom to Operate
- The validity of claims largely depends on prior art, including earlier antisense efforts and natural sequences.
- Key challenges include:
- Demonstrating inventive step over prior antisense approaches.
- Overcoming obviousness due to chemical modifications already existing by the patent date.
- Patent coverage remains strong in specific sequences and modifications but faces potential narrowness in scope.
Summary of Patent Scope
- Encompasses specific antisense sequences targeting HIV tat gene.
- Protects methods using chemical modifications.
- Limited to viral gene inhibition, particularly targeting a defined region of the HIV genome.
- The patent landscape is heavily concentrated with related patents on antisense technology and delivery platforms.
Key Takeaways
- US Patent 5,721,244 covers a method of inhibiting HIV using specific antisense oligonucleotides.
- Its claims are narrowly focused on sequences complementary to the tat gene, with chemical modifications and delivery methods included.
- The patent family includes multiple jurisdictions, with expiration around 2015.
- The antisense technology space for HIV has been highly active, with overlapping patent rights and significant R&D investment.
- Subsequent innovations in gene editing and RNA interference create potential research or development avenues outside the patent scope but may impact future therapies.
FAQs
Q1: Is US Patent 5,721,244 still in force?
A1: The patent expired around August 2015, based on the 20-year term from the filing date, unless extensions or adjustments were granted.
Q2: Can I develop a new HIV antisense therapy based on this patent?
A2: Likely yes, but careful patent landscape analysis is needed. Narrow claims limit infringement risk, especially if targeting different sequences or modifications.
Q3: Are there any active patents derived from this patent?
A3: Follow-on patents often cite or build upon this patent. Checking patent citation networks reveals newer patents in the antisense HIV space.
Q4: Does the patent cover all antisense therapies for HIV?
A4: No. It covers specific sequences and modifications targeting the tat gene. Other sequences and mechanisms are outside its scope.
Q5: How does this patent influence current antisense drug development for HIV?
A5: Its expiration opens opportunities for new therapies without infringement concerns; however, the existing patent landscape remains complex and highly active.
References
[1] U.S. Patent No. 5,721,244. (1998). Method for the inhibition of HIV replication and growth.
[2] Scherr, M., & Rossi, J. J. (2019). Antisense oligonucleotide-based therapeutics in HIV. Nature Reviews Drug Discovery, 18(4), 258–274.
[3] World Intellectual Property Organization (WIPO). (1996). WO 1996/017521.
[4] United States Patent and Trademark Office (USPTO). Patent Assignment Database.
[5] European Patent Office (EPO). Patent family documents and publication records.
More… ↓
⤷ Start Trial
|
